Plain-English translation of NCT07143136 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 1 โ Testing in a small group (usually 20โ80 people) to find a safe dose and watch for side effects.
This trial is testing whether , a medication that reduces inflammation in the body, can help improve outcomes in patients who have experienced a certain type of heart attack (non-ST elevation myocardial infarction) and are receiving a stent to open blocked arteries. Researchers believe that because inflammation plays a key role in heart disease, this medication might help reduce complications and improve recovery after the heart attack.
Some earlier studies suggested that this medication could reduce heart problems in patients with coronary artery disease, but limited information exists about using it right away during this specific type of heart attack. This trial will help doctors understand whether giving the treatment early, along with a stent procedure, can make a meaningful difference in patient outcomes.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
If you join this study, you will receive either the anti-inflammatory medication or standard care (determined by chance). You will take a loading dose of the medication before your stent procedure, then continue taking it daily for 3 months afterward. The research team will monitor your recovery, check inflammatory markers in your blood, and track your clinical outcomes over the short term to see if the treatment helps.
AI-generated summary from trial data ยท Jun 2, 2026 ยท Not medical advice
Egypt